Generic Eliquis Availability

Last updated on Jun 11, 2025.

See also: Generic Eliquis Sprinkle

Eliquis is a brand name of apixaban, approved by the FDA in the following formulation(s):

ELIQUIS (apixaban - tablet, for suspension;oral)

• Manufacturer: BRISTOL MYERS SQUIBB
  Approval date: April 17, 2025
  Strength(s): 0.5MG ^[RLD]

ELIQUIS (apixaban - tablet;oral)

• Manufacturer: BRISTOL MYERS SQUIBB
  Approval date: December 28, 2012
  Strength(s): 2.5MG ^{[RLD] [AB]}, 5MG ^{[RLD] [AB]}

Is there a generic version of Eliquis available?

A generic version of Eliquis has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Eliquis and have been approved by the FDA:

apixaban tablet;oral

• Manufacturer: ACCORD HLTHCARE
  Approval date: July 28, 2020
  Strength(s): 2.5MG ^[AB], 5MG ^[AB]
• Manufacturer: IMPAX
  Approval date: February 14, 2025
  Strength(s): 2.5MG ^[AB], 5MG ^[AB]
• Manufacturer: INDOCO
  Approval date: September 11, 2020
  Strength(s): 2.5MG ^[AB], 5MG ^[AB]
• Manufacturer: MACLEODS PHARMS LTD
  Approval date: February 27, 2025
  Strength(s): 2.5MG ^[AB], 5MG ^[AB]
• Manufacturer: TORRENT
  Approval date: December 17, 2024
  Strength(s): 2.5MG ^[AB], 5MG ^[AB]

Note: No generic formulation of the following product is available.

• apixaban - tablet, for suspension;oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eliquis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
  Patent 6,967,208
  Issued: November 22, 2005
  Inventor(s): Pinto; Donald J. P. et al.
  Assignee(s): Bristol-Myers Squibb Pharma Company (Princeton, NJ)
  

  The present application describes lactam-containing compounds and derivatives thereof of Formula I: ##STR1##
  or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

  Patent expiration dates:

  • November 21, 2026
    
    ✓ 
    Patent use: TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) AND REDUCTION IN THE RISK OF RECURRENT VTE IN PEDIATRIC PATIENTS WITH BODY WEIGHT FROM 4 TO LESS THAN 35 KG
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • November 21, 2026
    
    ✓ 
    Patent use: PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • November 21, 2026
    
    ✓ 
    Patent use: REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • November 21, 2026
    
    ✓ 
    Patent use: TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • November 21, 2026
    
    ✓ 
    Patent use: TREATMENT OF PULMONARY EMBOLISM (PE)
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • November 21, 2026
    
    ✓ 
    Patent use: REDUCING THE RISK OF STROKE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • November 21, 2026
    
    ✓ 
    Patent use: PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • November 21, 2026
    
    ✓ 
    Patent use: PROPHYLAXIS OF PULMONARY EMBOLISM
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • November 21, 2026
    
    ✓ 
    Patent use: REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT)
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • November 21, 2026
    
    ✓ 
    Patent use: REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • November 21, 2026
    
    ✓ 
    Patent use: TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) AND REDUCTION IN THE RISK OF RECURRENT VTE IN PEDIATRIC PATIENTS WITH BODY WEIGHT GREATER THAN OR EQUAL TO 35 KG
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
  Patent 6967208*PED
  Issued: November 22, 2005
  Inventor(s): Pinto; Donald J. P. et al.
  Assignee(s): Bristol-Myers Squibb Pharma Company (Princeton, NJ)
  

  The present application describes lactam-containing compounds and derivatives thereof of Formula I: ##STR1##
  or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

  Patent expiration dates:

  • May 21, 2027
    
    ✓ 
    Pediatric exclusivity
• Apixaban formulations
  Patent 9,326,945
  Issued: May 3, 2016
  Inventor(s): Patel; Jatin et al.
  Assignee(s): Bristol-Myers Squibb Company (Princeton, NJ); Pfizer Inc. (New York, NY)
  

  Compositions comprising crystalline apixaban particles having a D.sub.90 equal to or less than 89 μm, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.

  Patent expiration dates:

  • February 24, 2031
    
    ✓ 
    Drug product
• Apixaban formulations
  Patent 9326945*PED
  Issued: May 3, 2016
  Inventor(s): Patel; Jatin et al.
  Assignee(s): Bristol-Myers Squibb Company (Princeton, NJ); Pfizer Inc. (New York, NY)
  

  Compositions comprising crystalline apixaban particles having a D.sub.90 equal to or less than 89 μm, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.

  Patent expiration dates:

  • August 24, 2031
    
    ✓ 
    Pediatric exclusivity

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • April 17, 2028 - NEW PATIENT POPULATION
  • April 17, 2028 - NEW STRENGTH
  • October 17, 2028 - PEDIATRIC EXCLUSIVITY

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer